Current Atherosclerosis Reports

Papers
(The TQCC of Current Atherosclerosis Reports is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Revascularization Options for Left Main Disease: What Clinicians Need to Know169
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American Heart Association Scientific Sessions154
Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?125
Polysocial Risk Scores: Implications for Cardiovascular Disease Risk Assessment and Management122
The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes117
The Greatly Under-Represented Role of Smooth Muscle Cells in Atherosclerosis98
PCSK9 Inhibition and Risk of Diabetes: Should We Worry?73
Anti-apoC-III Therapies and Implications for Treatment of Pancreatitis and Cardiovascular Disease70
The Role of the PI3K/Akt/mTOR Pathway in Atherosclerosis: Mechanisms, Therapeutic Potential, and Emerging Targeted Treatments68
The Effects of FABP4 on Cardiovascular Disease in the Aging Population61
From ‘Omics to Multi-omics Technologies: the Discovery of Novel Causal Mediators60
Effects of Pioglitazone On Lipoprotein(a): A Meta-analysis52
Genetic Testing for Familial Hypercholesterolemia in Clinical Practice46
Salutary Effects of Nutritional Ketosis for the Diseased Human Heart45
Spontaneous Coronary Artery Dissection (SCAD): Unveiling the Enigma of the Unexpected Coronary Event44
The Intersection Between COVID-19, Cardiovascular Disease, and Diet: a Review43
Programmable Genome-Editing Technologies as Single-Course Therapeutics for Atherosclerotic Cardiovascular Disease41
Nutrition Interventions for Youth with Dyslipidemia: Who, What, When, and Where?39
Inflammation in the Peri-ACS Period: Ready for Prime Time?39
Percutaneous Coronary Interventions in Women38
Recent Advances and Perspectives of Metabolomics-Based Investigations in Coronary Heart Disease38
GLP-1 Receptor Agonists and Cardiovascular Disease: What Do Clinicians Need to Know?38
The Role of Non-Statin Lipid Lowering Therapies to Reduce ASCVD Events in Primary Prevention36
Lipid Lowering Therapy Utilization and Lipid Goal Attainment in Women36
ApoC-III as Therapeutic Target: Is it Primetime for Clinical Use?36
Lipoprotein(a): from Causality to Treatment35
The Emerging Specialty of Cardio-Rheumatology34
The Role of Sleep in Cardiovascular Disease33
Myeloid Cells in Abdominal Aortic Aneurysm33
In-Hospital Use of PCSK9 Inhibitors in the Post ACS Patient: What Does the Evidence Show?32
Importance of Nutrition Security to CVD Prevention Efforts in the USA32
The Role of Bacterial Extracellular Membrane Nanovesicles in Atherosclerosis: Unraveling a Potential Trigger32
Low LDL-C: Is It all Good News?32
Role of RNA-binding Proteins in Regulating Cell Adhesion and Progression of the Atherosclerotic Plaque and Plaque Erosion31
Can Clinical Biomarkers Guide Optimal Therapeutic Selection in Type 2 Diabetes Mellitus? A Scoping Review30
Implementing Reporting Standards for Polygenic Risk Scores for Atherosclerotic Cardiovascular Disease28
Effects of Omega-3 Fatty Acids on Flow-mediated Dilatation and Carotid Intima Media Thickness: A Meta-analysis28
Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) Equations: What Clinicians Need to Know?27
Novel Therapies for Lipoprotein(a): Update in Cardiovascular Risk Estimation and Treatment27
Coronary Microvascular Dysfunction: What Clinicians and Investigators Should Know26
Stress, Vascular Smooth Muscle Cell Phenotype and Atherosclerosis: Novel Insight into Smooth Muscle Cell Phenotypic Transition in Atherosclerosis26
Exploring the Role of SPARC in Atherosclerosis: Mechanisms and Potential Implications25
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American College of Cardiology Conference24
Transforming Population Health Screening for Atherosclerotic Cardiovascular Disease with AI-Enhanced ECG Analytics: Opportunities and Challenges23
Eliminating Health Disparities in Atrial Fibrillation, Heart Failure, and Dyslipidemia: A Path Toward Achieving Pharmacoequity23
Do Triglyceride-Rich Lipoproteins Equal Low-Density Lipoproteins in Risk of ASCVD?23
Is There a Role for Imaging Youth at Risk of Atherosclerosis?22
Noninvasive Atherosclerotic Phenotyping: The Next Frontier into Understanding the Pathobiology of Coronary Artery Disease22
Is Family History for the Management of Cardiovascular Health in Youth Still Relevant in Clinical Practice?22
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2025 European Society of Cardiology Conference22
Gene Regulatory Networks in Coronary Artery Disease22
Factors Affecting Circulating Phytosterol Levels: Toward an Integrated Understanding of Atherogenicity and Atheroprotection by Dietary and Circulating Phytosterols22
Membrane Cholesterol Interactions with Proteins in Hypercholesterolemia-Induced Endothelial Dysfunction22
HIV and Cardiovascular Disease Burden in Young Adults (18–25 years): A Review of Current Evidence21
Clinical Management of Dyslipidemia in Infants and Toddlers21
Brief Review: Racial and Ethnic Disparities in Cardiovascular Care with a Focus on Congenital Heart Disease and Precision Medicine21
Cardiovascular Disease in the Middle East and North Africa, 1990–2021: Burden, Trends, and Risk Factors21
What Causes Premature Coronary Artery Disease?20
Cardiovascular Health and Disease in the Pakistani American Population20
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2025 American College of Cardiology Conference20
Statin Use in Special Populations for the Prevention of Cardiovascular Disease in Adults20
Natural Sirtuin1 Activators and Atherosclerosis: an Overview20
Expanding Clinical Indications for Cardiac CT: A Review of Its Current Utility in American and European Guidelines20
Pharmacotherapy for Coronary Artery Disease and Acute Coronary Syndrome in the Aging Population19
High Density Lipoprotein Particle Composition, Functionality, Deficiency, and Atherosclerotic Cardiovascular Disease Risk: A Review19
Targeting the Gut Microbiome to Treat Cardiometabolic Disease18
A Review of Statin Intolerance: a Focus on Statin-Attributed Muscle Symptoms18
Inclisiran, Reasons for a Novel Agent in a Crowded Therapeutic Field18
Correlation Between Oral Bacteria and Atherosclerotic Thrombotic Disease: Advances in Animal Model Studies18
Utility of FFRCT in Patients with Chest Pain18
Extra-coronary Calcification and Cardiovascular Events: What Do We Know and Where Are We Heading?17
Fixed Combination for the Treatment of Dyslipidaemia17
Anti-Inflammatory Lipid Mediators from Polyunsaturated Fatty Acids: Insights into their Role in Atherosclerosis Microenvironments17
Circular RNA role in Atherosclerosis Development and Progression17
The Role of Lysyl Oxidase in the Pathological Stage of Atherosclerosis: Structural Stabilizer or Disease Driver?17
Dietary Management of Atherogenic Dyslipidemia16
Serial Coronary CTA for Monitoring Response to Lipid-Lowering Therapy: A Narrative Review16
Managing Dyslipidemia in Chronic Kidney Disease: Implications for Cardiovascular and Renal Risk16
Combined Dyslipidemia in Children and Adolescents: a Proposed New Management Approach16
0.115473985672